Immatics (IMTX) Competitors $4.60 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$4.63 +0.03 (+0.65%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IMTX vs. EWTX, ARWR, AMRX, MIRM, GMTX, MESO, IBRX, CNTA, HCM, and KYMRShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Edgewise Therapeutics (EWTX), Arrowhead Pharmaceuticals (ARWR), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Mesoblast (MESO), ImmunityBio (IBRX), Centessa Pharmaceuticals (CNTA), HUTCHMED (HCM), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Edgewise Therapeutics Arrowhead Pharmaceuticals Amneal Pharmaceuticals Mirum Pharmaceuticals Gemini Therapeutics Mesoblast ImmunityBio Centessa Pharmaceuticals HUTCHMED Kymera Therapeutics Edgewise Therapeutics (NASDAQ:EWTX) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability. Which has stronger earnings & valuation, EWTX or IMTX? Edgewise Therapeutics has higher earnings, but lower revenue than Immatics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$100.16M-$1.50-18.03Immatics$115.50M4.76-$104.98M-$0.66-6.98 Does the MarketBeat Community believe in EWTX or IMTX? Edgewise Therapeutics received 4 more outperform votes than Immatics when rated by MarketBeat users. However, 75.00% of users gave Immatics an outperform vote while only 72.34% of users gave Edgewise Therapeutics an outperform vote. CompanyUnderperformOutperformEdgewise TherapeuticsOutperform Votes3472.34% Underperform Votes1327.66% ImmaticsOutperform Votes3075.00% Underperform Votes1025.00% Do institutionals & insiders have more ownership in EWTX or IMTX? 64.4% of Immatics shares are owned by institutional investors. 24.1% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, EWTX or IMTX? Edgewise Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Is EWTX or IMTX more profitable? Edgewise Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -47.94%. Immatics' return on equity of -15.90% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -26.83% -25.67% Immatics -47.94%-15.90%-9.38% Do analysts rate EWTX or IMTX? Edgewise Therapeutics currently has a consensus target price of $41.29, suggesting a potential upside of 52.69%. Immatics has a consensus target price of $16.67, suggesting a potential upside of 261.93%. Given Immatics' stronger consensus rating and higher possible upside, analysts plainly believe Immatics is more favorable than Edgewise Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media prefer EWTX or IMTX? In the previous week, Edgewise Therapeutics had 4 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Edgewise Therapeutics and 2 mentions for Immatics. Edgewise Therapeutics' average media sentiment score of 0.47 beat Immatics' score of -0.26 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryImmatics beats Edgewise Therapeutics on 11 of the 18 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$549.63M$3.12B$5.80B$8.94BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-6.9830.1226.4118.84Price / Sales4.76320.52450.1476.68Price / CashN/A183.5344.0437.47Price / Book1.603.567.634.64Net Income-$104.98M-$71.72M$3.18B$245.69M7 Day Performance-8.81%-2.45%-1.82%-2.59%1 Month Performance-14.72%0.36%0.22%-2.30%1 Year Performance-61.66%-11.49%17.25%13.71% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics1.6278 of 5 stars$4.60flat$16.67+262.3%-59.5%$549.04M$115.50M-6.97260EWTXEdgewise Therapeutics1.8204 of 5 stars$26.34-0.1%$41.29+56.7%+54.8%$2.49BN/A-17.5660ARWRArrowhead Pharmaceuticals4.113 of 5 stars$19.92-1.6%$43.33+117.5%-28.3%$2.49B$3.55M-3.97400AMRXAmneal Pharmaceuticals3.786 of 5 stars$7.95+1.3%$10.00+25.8%+36.1%$2.46B$2.68B-11.697,700Positive NewsMIRMMirum Pharmaceuticals2.7335 of 5 stars$50.46-1.2%$57.10+13.2%+82.7%$2.42B$186.37M-24.98140GMTXGemini TherapeuticsN/A$54.82-2.6%N/A-17.4%$2.38BN/A-54.8230News CoverageMESOMesoblast0.8266 of 5 stars$18.68-4.2%$18.00-3.6%+757.2%$2.37B$5.90M0.0080Upcoming EarningsIBRXImmunityBio2.1054 of 5 stars$3.39+0.9%$13.58+300.7%-23.0%$2.36B$620,000.00-3.68590News CoverageCNTACentessa Pharmaceuticals3.461 of 5 stars$17.79-6.5%$25.83+45.2%+57.1%$2.35B$6.85M-11.63200Insider TradeHigh Trading VolumeHCMHUTCHMED1.6307 of 5 stars$13.42+1.4%$19.00+41.6%+6.3%$2.34B$610.81M0.001,988Upcoming EarningsNews CoverageGap UpKYMRKymera Therapeutics2.3671 of 5 stars$36.04-3.4%$55.06+52.8%-1.6%$2.33B$78.59M-15.40170News CoverageGap Up Related Companies and Tools Related Companies Edgewise Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Gemini Therapeutics Competitors Mesoblast Competitors ImmunityBio Competitors Centessa Pharmaceuticals Competitors HUTCHMED Competitors Kymera Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
